CalciMedica Announces Presentations at Upcoming Medical Meetings

CALC 11.20.2024

Full Press ReleaseSEC FilingsOur CALC Tweets

About Gravity Analytica

Recent News

  • 01.14.2025 - CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors
  • 12.04.2024 - Piper Sandler 36th Annual Healthcare Conference
  • 11.21.2024 - CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference

Recent Filings

  • 01.16.2025 - 3 Initial statement of beneficial ownership of securities
  • 01.16.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.14.2025 - 8-K Current report

Prof.Robert Suttontodeliver plenary presentation on Phase 2b CARPO trial of AuxoraTM in Acute Pancreatitis (AP) atAmerican Pancreatic Association(APA) 2024 Annual Meeting

Poster presentation onPhase 2b CARPO trialat Emergencies in Medicine (EIM) 2024 Meeting

LA JOLLA, Calif.,Nov. 20, 2024/PRNewswire/ --CalciMedica Inc.("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the acceptance of an abstract for plenary presentation at theAmerican Pancreatic Association(APA) 2024 Annual Meeting being heldDecember 9-10inMaui, HI, and the acceptance of an abstract for poster presentation at the Emergencies in Medicine (EIM) 2024 Meeting being heldDecember 8-13inMaui, HI.

CalciMedica Logo (PRNewsfoto/CalciMedica, Inc.)

Details for the presentations are as follows:

Plenary Presentation at APA 2024 Annual Meeting

Presentation Title:Auxora Decreases the Development of Severe Organ Failure in Patients with Acute Pancreatitis and SIRS

Presenter:Prof.Robert Sutton,B.A.(Hons), M.B., B.S.,D.Phil., FRCS,University of LiverpoolandLiverpool University Hospitals NHS Foundation Trust

Session Title:Abstract Session 2 – Pancreatitis

Session Date and Time:Tuesday, December 10,8:00-9:30 a.m. HST

Poster Presentation at EIM 2024 Meeting

Presentation Title:A Randomized, Double-Blind, Placebo Controlled Dose Ranging Study of Auxora in Patients with Acute Pancreatitis (AP) and Accompanying Systemic Inflammatory Response Syndrome (SIRS)- CARPO (NCT0468106)

The presentation and poster will be available following the sessions on the Medical Events & Presentations section ofCalciMedica'sIR website athttps://ir.calcimedica.com/news-events/medical-events-publications.

AboutCalciMedicaCalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate AuxoraTM has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced topline data for a Phase 2b trial (called CARPO –NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS) and completed a Phase 2 trial (called CARDEA –NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE –NCT06374797) in patients with acute kidney disease (AKI) with associated acute hypoxemic respiratory failure (AHRF) with data expected in 2025 and continuing to support the ongoing Phase 1/2 trial (called CRSPA –NCT04195347) in pediatric patients with asparaginase-induced pancreatic toxicity (AIPT) with data expected in 2025. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visitwww.calcimedica.com.

Forward-Looking StatementsThis communication contains forward-looking statements which include, but are not limited to,CalciMedica'songoing and planned clinical trials and the timing, design, expected patient enrollment thereof and the expected timing for the release of data from those trials, including its Phase 2b CARPO trial of Auxora for AP with accompanying SIRS, its ongoing Phase 1/2 CRSPA trial of Auxora in pediatric patients with AIPT, and its planned Phase 2 KOURAGE trial of Auxora in AKI with associated AHRF; the potential benefits of Auxora for the treatment of AP, AKI and AIPT; and the potential ofCalciMedica'sproprietary technology to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995.CalciMedica'sexpectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances. Risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption "Risk Factors" inCalciMedica'sAnnual Report on Form 10-K for the year endedDecember 31, 2023, and elsewhere inCalciMedica'ssubsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with theSECfrom time to time and available atwww.sec.gov. These documents can be accessed onCalciMedica'sweb page atir.calcimedica.com/financials-filings/sec-filings. The forward-looking statements contained herein are made as of the date hereof, andCalciMedicaundertakes no obligation to update them after this date, except as required by law.

CalciMedica Contact:

Investors and MediaArgot PartnersSarah Sutton/Kevin Murphycalcimedica@argotpartners.com(212) 600-1902

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-announces-presentations-at-upcoming-medical-meetings-302312062.html

SOURCECalciMedica, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com